Li Mao
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: July 08, 2026
Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.
Journal: OncoTargets and therapy
Published: March 12, 2021
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer.
Journal: Translational lung cancer research
Published: February 11, 2021
Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients.
Journal: Frontiers in oncology
Published: December 30, 2020
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: December 28, 2020
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 16, 2020
Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: August 26, 2020
Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration.
Journal: Cancer chemotherapy and pharmacology
Published: April 30, 2020
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 17, 2019
First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.
Journal: Journal of hematology & oncology
Published: August 26, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Journal: The Lancet. Respiratory medicine
Published: April 26, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026